Table 1.
Clinical characteristics of patients with EOC diagnosed with BM, by mutation category
| Clinical characteristic |
BRCA1/2 positive n=21 n (%) |
BRCA1/2 negative n= 42 n (%) | p-value |
|---|---|---|---|
| Median age at diagnosis (range) | 54.0 (36–80) | 59.5 (41–86) | 0.28 |
| Histology | |||
| High-grade serous | 21 (100) | 35 (83) | 0.56 |
| Carcinoma, NOS | 0 (0) | 1 (2) | |
| Mixed histology | 0 (0) | 2 (5) | |
| Endometrioid | 0 (0) | 1 (2) | |
| Clear cell | 0 (0) | 1 (2) | |
| Carcinosarcoma | 0 (0) | 2 (5) | |
| Low-grade serous | 0 (0) | 0 (0) | |
| Stage at diagnosis | |||
| I/II | 0 (0) | 1 (2) | 0.48 |
| III/IV | 21 (100) | 41 (98) | |
| Primary treatment | |||
| PDS | 11 (52) | 21 (50) | 0.86 |
| NACT | 10 (48) | 21 (50) | |
| Debulking surgery (primary or interval) | |||
| Optimal | 18 (86) | 33 (79) | 0.76 |
| Sub-optimal | 0 (0) | 0 (0) | |
| Unknown/did not have surgery | 3 (14) | 9 (21) | |
| Intraperitoneal chemotherapy | |||
| Received | 10 (48) | 11 (26) | 0.09 |
| Did not receive | 11 (52) | 31 (74) | |
| Platinum sensitivity at first recurrence | |||
| Sensitive | 17 (81) | 26 (62) | 0.13 |
| Resistant | 4 (19) | 16 (38) | |
NOS, not otherwise specified; PDS, primary debulking surgery; NACT, neoadjuvant chemotherapy